Stockreport

?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 [Yahoo! Finance]

Invivyd, Inc.  (IVVD) 
PDF fourth-quarter 2025 net product revenue of $17.2 million from PEMGARDA (pemivibart), representing 25% growth year over year and a 31% increase from the prior quarter. Th [Read more]